berberine has been researched along with Metabolic Diseases in 17 studies
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc." | 9.12 | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. ( Cai, B; Chen, Q; Wang, S; Xu, Z, 2021) |
| "Berberine (BBR) is a multi-target drug (MTD) that has proven effective in the treatment of metabolism-related chronic diseases (CDs)." | 9.05 | Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. ( Foiani, M; Jiang, JD; Kong, WJ; Vernieri, C, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 8.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| "Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years." | 6.61 | Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. ( Annunziata, G; Barrea, L; Barreca, D; Feng, X; Hassan, STS; Jafari, S; Mahomoodally, MF; Malaník, M; Memariani, Z; Nabavi, SM; Shen, AZ; Šmejkal, K; Sureda, A; Sychrová, A; Tewari, D; Xu, S; Zengin, G; Ziberna, L, 2019) |
| " Various in vitro and in vivo studies have reported the anti-inflammatory role of berberine (BRB), an organic heteropentacyclic phytochemical and natural isoquinoline, in inhibiting NLRP3 inflammasome-dependent inflammation against many disorders." | 5.12 | Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases. ( Abrahamse, H; George, BP; Sarbadhikary, P, 2021) |
| "Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc." | 5.12 | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. ( Cai, B; Chen, Q; Wang, S; Xu, Z, 2021) |
| "Berberine (BBR) is a multi-target drug (MTD) that has proven effective in the treatment of metabolism-related chronic diseases (CDs)." | 5.05 | Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. ( Foiani, M; Jiang, JD; Kong, WJ; Vernieri, C, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 4.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| " Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials." | 3.96 | Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. ( Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK, 2020) |
| "Berberine is a plant metabolite belonging to the group of isoquinoline alkaloids with strong biological and pharmacological activity." | 2.66 | Biological Activity of Berberine-A Summary Update. ( Nowak, R; Och, A; Podgórski, R, 2020) |
| "Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years." | 2.61 | Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. ( Annunziata, G; Barrea, L; Barreca, D; Feng, X; Hassan, STS; Jafari, S; Mahomoodally, MF; Malaník, M; Memariani, Z; Nabavi, SM; Shen, AZ; Šmejkal, K; Sureda, A; Sychrová, A; Tewari, D; Xu, S; Zengin, G; Ziberna, L, 2019) |
| "Berberine is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids found in such plants as gender Berberis." | 2.53 | Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders. ( Caliceti, C; Cicero, AF; Franco, P; Roda, A; Spinozzi, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 9 (52.94) | 2.80 |
| Authors | Studies |
|---|---|
| Sarbadhikary, P | 1 |
| George, BP | 1 |
| Abrahamse, H | 1 |
| Pu, Z | 1 |
| Sun, Y | 1 |
| Jiang, H | 1 |
| Hou, Q | 1 |
| Yan, H | 1 |
| Wen, H | 1 |
| Li, G | 1 |
| Cazzaniga, M | 2 |
| Zonzini, GB | 1 |
| Di Pierro, F | 1 |
| Moricoli, S | 1 |
| Bertuccioli, A | 1 |
| Ye, C | 1 |
| Zhang, Y | 1 |
| Lin, S | 1 |
| Chen, Y | 1 |
| Wang, Z | 1 |
| Feng, H | 1 |
| Fang, G | 1 |
| Quan, S | 1 |
| Kong, WJ | 1 |
| Vernieri, C | 1 |
| Foiani, M | 1 |
| Jiang, JD | 2 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Singh, DP | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Wang, S | 1 |
| Xu, Z | 1 |
| Cai, B | 1 |
| Chen, Q | 1 |
| Xu, X | 1 |
| Yi, H | 1 |
| Wu, J | 1 |
| Kuang, T | 1 |
| Zhang, J | 1 |
| Li, Q | 1 |
| Du, H | 1 |
| Xu, T | 1 |
| Jiang, G | 1 |
| Fan, G | 1 |
| Och, A | 1 |
| Podgórski, R | 1 |
| Nowak, R | 1 |
| Brown, BI | 1 |
| Bonanni, B | 1 |
| Feng, X | 1 |
| Sureda, A | 1 |
| Jafari, S | 1 |
| Memariani, Z | 1 |
| Tewari, D | 1 |
| Annunziata, G | 1 |
| Barrea, L | 1 |
| Hassan, STS | 1 |
| Šmejkal, K | 1 |
| Malaník, M | 1 |
| Sychrová, A | 1 |
| Barreca, D | 1 |
| Ziberna, L | 1 |
| Mahomoodally, MF | 1 |
| Zengin, G | 1 |
| Xu, S | 1 |
| Nabavi, SM | 1 |
| Shen, AZ | 1 |
| Guo, HH | 1 |
| Feng, CL | 1 |
| Zhang, WX | 1 |
| Luo, ZG | 1 |
| Zhang, HJ | 1 |
| Zhang, TT | 1 |
| Ma, C | 1 |
| Zhan, Y | 1 |
| Li, R | 1 |
| Wu, S | 1 |
| Abliz, Z | 1 |
| Li, C | 1 |
| Li, XL | 1 |
| Ma, XL | 1 |
| Wang, LL | 1 |
| Zheng, WS | 1 |
| Han, YX | 1 |
| Liu, Q | 1 |
| Yang, X | 1 |
| Chang, RC | 1 |
| Caliceti, C | 1 |
| Franco, P | 1 |
| Spinozzi, S | 1 |
| Roda, A | 1 |
| Cicero, AF | 1 |
| Shen, N | 1 |
| Li, CN | 1 |
| Huan, Y | 1 |
| Shen, ZF | 1 |
| Lin, H | 1 |
| Li, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assess the Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus Among Individuals With High Cardiometabolic Risk[NCT05749874] | Phase 4 | 6,500 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| A Phase I, Randomized, Crossover, Double-blind, Pharmacokinetic Study of Berberine Released From Cyclodextrin in Healthy Volunteers[NCT04918667] | Phase 1 | 16 participants (Anticipated) | Interventional | 2024-09-30 | Not yet recruiting | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for berberine and Metabolic Diseases
| Article | Year |
|---|---|
Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Humans; Inflammasomes; Inflammation; Metabolic Disease | 2021 |
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.
Topics: Animals; Berberine; Chronic Disease; Drug Delivery Systems; Energy Metabolism; Humans; Metabolic Dis | 2020 |
Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine.
Topics: Animals; Berberine; Drug Delivery Systems; Gastrointestinal Microbiome; Humans; Insulin Resistance; | 2021 |
Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence.
Topics: Animals; Berberine; Biological Availability; Energy Metabolism; Humans; Metabolic Diseases; Signal T | 2021 |
Biological Activity of Berberine-A Summary Update.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Berberine; Cardiovascular Diseases; Drug R | 2020 |
Nutritional Management of Metabolic Endotoxemia: A Clinical Review.
Topics: Anti-Infective Agents; Berberine; Diet Therapy; Dysbiosis; Endotoxemia; Fermentation; Glutamine; Hum | 2017 |
Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
Topics: Berberine; Blood Glucose; Breast Neoplasms; Female; Humans; Incidence; Insulin Resistance; Metabolic | 2018 |
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.
Topics: Animals; Berberine; Cardiovascular Diseases; Cardiovascular System; Humans; Metabolic Diseases | 2019 |
Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders.
Topics: Animals; Berberine; Humans; Metabolic Diseases | 2016 |
[Advances of the mechanism study on berberine in the control of blood glucose and lipid as well as metabolism disorders].
Topics: AMP-Activated Protein Kinase Kinases; Animals; Berberine; Blood Glucose; Coptis; Diabetes Mellitus; | 2010 |
1 trial available for berberine and Metabolic Diseases
| Article | Year |
|---|---|
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Berberine; Gastrointestinal Microbiome; Humans; Metabolic Dis | 2021 |
6 other studies available for berberine and Metabolic Diseases
| Article | Year |
|---|---|
Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis.
Topics: Berberine; Breast Neoplasms; Butyrates; Dysbiosis; Estrogens; Fatty Acids, Volatile; Female; Gastroi | 2022 |
Berberine Ameliorates Metabolic-Associated Fatty Liver Disease Mediated Metabolism Disorder and Redox Homeostasis by Upregulating Clock Genes: Clock and Bmal1 Expressions.
Topics: Animals; ARNTL Transcription Factors; Berberine; Glucosamine; Hep G2 Cells; Homeostasis; Humans; Hyd | 2023 |
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female | 2020 |
Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases.
Topics: Animals; Berberine; Caco-2 Cells; Cardiovascular Diseases; Dyslipidemias; Hep G2 Cells; Humans; Hypo | 2019 |
Editorial: Bioactive Small Molecules in Regulating Inflammation and Metabolic Disorder.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Humans; Inflammation; Metabol | 2016 |
Adiponectin self-regulates its expression and multimerization in adipose tissue: an autocrine/paracrine mechanism?
Topics: Adiponectin; Adipose Tissue; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Autocrine Co | 2012 |